The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Nishikawa, Hiroki ^a   Iguchi, Eriko ^a   Koshikawa, Yorimitsu ^a   Ako, Soichiro ^a   Inuzuka, Tadashi ^a   Takeda, Haruhiko ^a   Nakajima, Jun ^a   Matsuda, Fumihiro ^a   Sakamoto, Azusa ^a   Henmi, Sinichiro ^a   Hatamaru, Keiichi ^a   Ishikawa, Tetsuro ^a   Saito, Sumio ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Elderly patients; Pegylated interferon; Ribavirin; Treatment response

Indexed keywords

HEPATITIS C VIRUS;

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

AGED; ARTICLE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MIDDLE AGED; MOLECULAR TYPING; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; SEX DIFFERENCE; THROMBOCYTE; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

AGED; ANTIVIRAL AGENTS; BLOOD PLATELETS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR TYPING; MULTIVARIATE ANALYSIS; PLATELET COUNT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SEX FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84857935545     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-135     Document Type: Review

References (28)

1. Di Bisceglie AM, Hepatitis C, Lancet 1998 351 351 355 10.1016/S0140-6736(97)07361-3 9652633 (Pubitemid 28052709)
2. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained viological responders. Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N, J Viral Hepat 2010 17 185 191 10.1111/j.1365-2893.2009.01163.x 19709362
3. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saito S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H, Intervirology 2007 50 16 23 10.1159/000096308 17164553 (Pubitemid 46005267)
4. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ, Proc Natl Acad Sci USA 2002 99 15584 15589 10.1073/pnas.242608099 12438687 (Pubitemid 35403976)
5. Incident hepatitis C virus infection in a community-based population in Japan. Okayama A, Stuver SO, Tabor E, Tachibana N, Kohara M, Mueller NE, Tsubouchi H, J Viral Hepat 2002 9 1 43 51 10.1046/j.1365-2893.2002.00331.x 11851902 (Pubitemid 36002486)
6. Appendix: the national institutes of health consensus development conference management of hepatitis C 2002. Seeff LB, Hoofnagle JH, Clin Liver Dis 2003 7 261 287 10.1016/S1089-3261(02)00078-8 12691470 (Pubitemid 36350763)
7. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, Lancet 2001 358 958 965 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
8. Peginteferon alfa-2a plus ribavirn for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J, N Engl J Med 2002 347 975 982 10.1056/NEJMoa020047 12324553
9. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. McHutchson JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, N Eng J Med 2009 360 1827 1838 10.1056/NEJMoa0806104
10. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. Huang CF, Yang JF, Dai CY, Huang JF, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML, J Infect Dis 2010 201 705 709
11. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 year. Antonucci G, Longo MA, Angeletti C, Vario F, Oliva A, Comandini UV, Tocci G, Boumis E, Noto P, Solmone MC, Capobianchi MR, Girardi E, Am J Gastroenterology 2007 102 1383 1391 10.1111/j.1572-0241.2007.01201.x (Pubitemid 46976284)
12. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? Floreani A, Minola E, Carderi I, Ferrara F, Rizzotto ER, Baldo V, J Am Geriatr Soc 2006 54 549 550 10.1111/j.1532-5415.2006.00643-4.x 16551333 (Pubitemid 43327180)
13. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Bedossa P, Poynald T, Hepatology 1996 24 289 293 10.1002/hep.510240201 8690394 (Pubitemid 26260021)
14. Management of hepatitis C: June 10-12, 2002. National Institutes of Health Consensus Development Conference Statement, Hepatology 2002 36 Suppl 3 20 12407572
15. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY, J Clin Microbiol 1997 35 201 7 8968908 (Pubitemid 26422655)
16. American association for the study of liver diseases. Diagnosis, management, and treatment of hepatitis C. Strader DB, Wright T, Thomas DL, Seeff LB, Hepatology 2004 39 4 1147 71 10.1002/hep.20119 15057920 (Pubitemid 38428955)
17. International hepatitis interventional therapy group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK, Gastroenterology 2002 123 1061 69 10.1053/gast.2002.35950 12360468
18. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Poynard T, Bedossa P, Opolon P, Lancet 1997 349 825 832 10.1016/S0140-6736(96)07642-8 9121257 (Pubitemid 27129209)
19. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Hamada H, Yatsuhashi H, Yano K, Daikoku M, Arisawa K, Inoue O, Koga M, Nakata K, Eguchi K, Yano M, Cancer 2002 95 331 339 10.1002/cncr.10662 12124834 (Pubitemid 34787600)
20. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Antonucci G, Longo MA, Angeletti C, Vario F, Oliva A, Comandini UV, Tocci G, Boumis E, Noto P, Solmone MC, Capobianchi MR, Girardi E, Am J Gastroenterology 2007 102 1383 1391 10.1111/j.1572-0241.2007.01201.x (Pubitemid 46976284)
21. Limitation of Combination Therapy of Interferon and Ribavirin for Older Patients With Chronic Hepatitis C. Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Shimoe T, Takaguchi K, Hashimoto N, Kobatake T, Tomita M, Kawaguchi M, Kobashi H, Sakaguchi K, Shiratori Y, Hepatology 2006 43 54 63 10.1002/hep.20984 16374855 (Pubitemid 43733592)
22. Efficacy of peginterferon - 2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Honda T, Katano Y, Simizu J, Ishizu Y, Doizaki M, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H, Liver Int 2010 30 527 537 10.1111/j.1478-3231. 2009.02064.x 19523048
23. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged years and more. Edoardo GG, Monica B, Vincenzo S, Antonino P, Dig Dis Sci 2010 55 3193 3199 10.1007/s10620-010-1408-x 20848200
24. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Kaytayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N, J Hepatology 2011 54 604 611 10.1016/j.jhep.2010.07.043
25. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N, J Viral Hepat 2009 16 578 585 10.1111/j.1365-2893.2009. 01116.x 19552663
26. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N, J Viral Hepat 2009 16 586 595 10.1111/j.1365-2893.2009.01106.x 19552664
27. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team, N Engl J Med 2009 361 580 593 10.1056/NEJMoa0808010 19625712
28. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H, Dig Dis Sci 2009 54 1317 1324 10.1007/s10620-008-0500-y 18958621